Michael J. Higgins
Entrepreneur-in-residence at Polaris Partners
Chairman of the PULMATRiX Board of Directors

Mr. Higgins was appointed to serve as a director of PULMATRiX in March 2015. Mr. Higgins is currently an entrepreneur-in-residence at Polaris Partners and is a board member at Genocea Biosciences, Voyager Therapeutics, Kindex Pharmaceuticals, Madauder Therapeutics, Sea Pharmaceuticals, and ...see more Private Equity Access Fund, II. Mr. Higgins served as senior vice president, chief operating officer, and chief financial officer of Ironwood Pharmaceuticals Inc. and led its finance, operations, and strategy efforts from 2003 to 2014 and through its initial public offering and the launch of its first commercial product. Prior to 2003, Mr. Higgins spent seven years and held a variety of senior business positions at Genzyme Corporation, including vice president of corporate finance and vice president of business development. Prior to joining Genzyme Corporation, Mr. Higgins led Procept, Inc. from founding through its initial public offering. Mr. Higgins earned a BS from Cornell University and an MBA from the Amos Tuck School of Business Administration at Dartmouth College. ...see less

Mark Iwicki
Executive Chairman, Kala Pharmaceuticals

Mr. Iwicki has 25 years’ experience as a pharmaceutical industry leader managing all stages of drug development and commercialization in multiple therapeutic areas, including respiratory. He was CEO of Civitas Pharmaceuticals, a biotechnology company with a novel pulmonary drug delivery platform. ...see more He also led the development and launch of several respiratory products as CEO of Sunovion Pharmaceuticals and during his tenure at Novartis. Mr. Iwicki is currently on the boards of directors of Kala Pharmaceuticals, Aimmune, Nimbus Therapeutics, and Merus. ...see less

Amit D. Munshi
Director, President and Chief Executive Officer, Arena Pharmaceuticals

MAmit D. Munshi was appointed to serve as a director of PULMATRiX in June 2017. He is currently the President and Chief Executive Officer of Arena Pharmaceuticals, Inc. Previously, Mr. Munshi served as President and Chief Executive Officer and a director of Epirus Biopharmaceuticals, Inc. from May 2012 to May 2016. ...see more Prior to Epirus, Mr. Munshi served as Chief Executive Officer of Percivia LLC, a biotechnology company, from 2011 to 2012, was a co-founder and served as Chief Business Officer of Kythera Biopharmaceuticals, Inc., from 2005 to 2010, and held multiple leadership positions at Amgen Inc. from 1997 to 2005, including General Manager, Nephrology Europe. Mr. Munshi holds a BS in Economics and a BA in History from the University of California, Riverside, and an MBA from the Peter F. Drucker Graduate School of Management at Claremont Graduate University. Mr. Munshi has more than 25 years of global biopharmaceutical industry experience in executive management, business development, product development, and portfolio management. Mr. Munshi currently serves on the board of Cytrellis Biosystems, Inc. ...see less

Ted Raad
Chief Executive Officer and Director

Mr. Raad was appointed Chief Executive Officer in 2019. Prior to his appointment, he served as PULMATRiX’s Chief Business Officer and led commercial and business development efforts. He has 20 years of commercial healthcare and life science leadership experience and most recently served ...see more as Chief Commercial Officer at Option Care, where he helped separate the specialty home infusion business unit from Walgreens to create the nation’s largest independent home infusion provider. Prior to that, he was a business unit head at Sunovion with overall responsibility for CNS and respiratory products, including assets in asthma and COPD. During his time at Sunovion, Mr. Raad led multiple products through clinical development to commercialization and implemented new strategic alliances in the US and Japan. Earlier in his career, he also gained direct launch experience with Sporanox, Janssen’s oral itraconazole product to treat fungal infections, and brings that experience to the PULMATRiX PUR1900 program. Mr. Raad holds a BS in Business Administration from University of Colorado at Boulder and an MBA from Thunderbird Global School of Global Management. ...see less

Rick Batycky
Chief Executive Officer, Nocion Therapeutics

Dr. Batycky has over two decades of experience with biotech start-ups from founding to acquisition across an array of platforms and disease states with significant expertise in inhaled drug development. Most recently, he was the Chief Scientific Officer and a founder of Civitas Therapeutics, which was acquired by Acorda. ...see more At Acorda, he was Chief Technology Officer where he led its novel dry powder inhalation therapy to treat motor issues in Parkinson's patients through to FDA approval as Inbrija™. Prior to that he was Chief Scientific Officer and Senior VP of R&D at Pulmatrix and held prior positions at Alkermes and Advanced Inhalation Research. Dr. Batycky received his B.Sc. in Chemical Engineering from the University of Calgary and his S.M. and Ph.D. in Chemical Engineering from the Massachusetts Institute of Technology (MIT). ...see less

Chris Cabell MD, MHS, FACC
Executive Vice President, Head of Research and
Development, and Chief Medical Officer at Arena

Dr. Chris Cabell is the Executive Vice President, Head of Research and Development, and Chief Medical Officer at Arena Pharmaceuticals. Prior to joining Arena, Dr. Cabell spent 10 years at Quintiles Inc and QuintilesIMS in a variety of management positions including Chief Medical and Scientific Officer, Global Head of Medical and Project Management, and Global Head of Business Development. ...see more Prior to joining Quintiles, Dr. Cabell was on faculty at Duke University School of Medicine in the Division of Cardiology. Dr. Cabell is a Fellow of the American College of Cardiology and has over 100 peer reviewed publications including in the New England Journal of Medicine, JAMA, and Annals of Internal Medicine. Board certified in both internal medicine and cardiovascular diseases, Dr. Cabell is a honors graduate of Pennsylvania State University and Duke University, earning both his Medical Degree and a Masters in Health Sciences from the latter. ...see less

Todd Bazemore
Chief Operating Officer, Kala Pharmaceuticals

Mr. Bazemore is a biopharmaceutical executive with more than 25 years of experience spanning from ultra-rare orphan diseases to large primary care conditions. He is currently the Chief Operating Officer of Kala Pharmaceuticals, a company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye. ...see more Prior to joining Kala Pharmaceuticals in 2017, Mr. Bazemore served as Executive Vice President and Chief Operating Officer of Santhera Pharmaceuticals (USA), Inc. Prior to joining Santhera U.S., he served as Executive Vice President and Chief Commercial Officer of Dyax Corp. before its acquisition by Shire Plc in January of 2016. Prior to joining Dyax, Mr. Bazemore was at Sunovion Pharmaceuticals, Inc. (previously Sepracor Inc., prior to its acquisition by Sumitomo Dainippon Pharma Co., Ltd), where he served in several roles of increasing responsibility, including Vice President of the Respiratory Business Unit....see less